ONLINE MUTATION REPORT

Ser19→Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people

M Vrablík, A Hořínek, R Češka, V Adámková, R Poledne, J A Hubacek

J Med Genet 2003;40:e105(<http://www.jmedgenet.com/cgi/content/full/40/8/e105>)

Cardiovascular disease (CVD) is the most common cause of death in industrialised countries. Raised plasma triglycerides (TGs) have been shown to be an independent risk factor for CVD.¹

Recently, a new gene designated *APOAV* has been identified in the *APOAI/APOCIII/APOAIV* gene cluster by comparative sequencing by Pennacchio *et al.*² The human *APOAV* gene consists of four exons and codes for a 369 amino acid protein, which is only expressed in the liver. Generation of transgenic and knockout mice assessed the importance of this gene for plasma TG determination. The transgenic mice show decreased and the knockout mice increased concentrations of plasma TGs, whereas the plasma cholesterol concentrations are not influenced significantly.

In the human *APOAV* gene, T-1131C (originally referred to as SNP3) and Ser19→Trp polymorphisms have been detected.²⁻⁴ Associations between these polymorphisms and TG concentrations have been found in healthy, non-smoking subjects not receiving lipid lowering medication as well as in different population samples. The C allele of the T-1131C polymorphism was found to be associated with extreme concentrations of plasma TGs.^{5,6}

The aim of this study was to evaluate the putative association of a common *APOAV* variation (Ser19→Trp) in those with extreme plasma TG concentrations.

SUBJECTS AND METHODS

The patients were selected from the database of the Prague Lipid Clinic of the 3rd Internal Department, which actively follows almost 2500 patients and has more than 30 years' experience in the diagnosis and treatment of lipid metabolism disorders. The group of patients consisted of 83 unrelated people (67 men and 16 women) aged 50.2 (SD 9.3) years with extreme lipid indices (TGs of 20.4 (SD 12.8) mmol/l and total cholesterol of 10.4 (SD 3.7) mmol/l). For inclusion in the study, initial lipid concentrations measured without any lipid lowering medication were considered.

In all patients the lipoprotein lipase (*LPL*) gene has been screened with heteroduplex analysis in an effort to detect some mutations.

A control group consisted of 2559 unrelated white people (1191 men and 1368 women, aged 28–67 years) selected as a 1% representative Czech population sample recruited as a follow up to the MONICA study. Their plasma lipid concentrations were as follows: TGs 2.0 (SD 1.3) mmol/l (men) and 1.5 (SD 0.8) mmol/l (women); and total cholesterol 5.8 (SD 1.0) mmol/l (men) and 5.8 (SD 1.2) mmol/l (women). Body mass index and smoking prevalence in the control group were comparable with the patient group, but there were more diabetic people among the patients (39.0% v 5.2%). Written informed consent was obtained from the study participants and the local ethics committee approved the design of the study.

DNA was isolated by a standard salting out method.⁷ Oligonucleotides AV1-F 5' TGC TCA CCT GGG CTC TGG CTC TTC and AV1-R 5' CCA GAA GCC TTT CCG TGC CTG GGC GGC

Key points

- A new apolipoprotein AV gene has been identified, which is expressed just in the liver. Generation of transgenic and knockout mice assessed the importance of apoAV for plasma triglyceride determination. Associations between T-1131→C and Ser19→Trp polymorphisms and plasma triglycerides have been found in population samples.
- This prompted us to study the Ser19→Trp polymorphism in 83 unrelated patients with extreme lipid indices (triglycerides of 20.4 (SD 12.8) mmol/l and total cholesterol of 10.4 (SD 3.7) mmol/l) and in a control group consisting of 2559 unrelated white people.
- In patients, the frequency of carriers of the Ser/Trp and Trp/Trp genotypes was much higher (30.1% v 14.1%, $p < 0.0001$) compared to the population sample. This suggested a strong association between the Ser19→Trp polymorphism in the *APOAV* gene and extreme concentrations of plasma triglycerides.

were used to amplify an *APOAV* fragment as described previously.^{5,6} The polymerase chain reaction product (10 µl) was digested with 10 U of *Eco52I* (Fermentas) at 37°C overnight. The restriction fragments were analysed by 10% polyacrylamide microtitre array diagonal gel electrophoresis,⁸ stained with ethidium bromide, and visualised on a UV trans-illuminator.

The lipoprotein indices were measured enzymatically in the Regional Lipid Reference Centre, IKEM, Prague, with a Roche COBAS MIRA autoanalyser, using conventional enzymatic methods. Body mass index was calculated as weight in kg divided by height in metres squared.

Statistical analysis was performed using the χ^2 test with Yates's correction.

RESULTS AND DISCUSSION

Heteroduplex analysis of the *LPL* gene did not detect any mutation in the 83 hypertriglyceridaemic patients; neither in the population nor in patient groups was *APOAV* polymorphism associated with diabetes.

The pattern of distribution of *APOAV* genotypes is summarised in table 1. The frequency of carriers of the Ser/Trp and Trp/Trp genotypes was much higher ($p < 0.0001$) in patients with extreme TG concentrations compared to the population sample. Although not all hypertriglyceridaemic patients have the Trp allele, this result supports the importance of the *APOAV* gene in genetic determination of plasma TG concentrations.

Abbreviations: *APOAV*, apolipoprotein AV; CVD, cardiovascular disease; *LPL*, lipoprotein lipase; TGs, triglycerides;

Table 1 Allele distribution of the Ser19→Trp polymorphism in the APOAV gene in hypertriglyceridaemic patients and in controls (p<0.0001)

	Ser19→Trp polymorphism			
	Controls (2559)		Patients (83)	
	No	%	No	%
Ser/Ser	2198	85.9	58	69.9
Ser/Trp	352	13.8	22	26.5
Trp/Trp	9	0.3	3	3.6

Pennacchio *et al*⁴ have found a higher frequency (23% *v* 9.5%) of Trp19 carriers in 82 male patients with plasma TG >90% compared to 82 patients from the opposite end of the distribution curve (TG <10%). A similar association was found in the groups of 50 and 50 females selected. A similar association was found in the groups of 50 and 50 females selected according to the same criteria (22% *v* 0%).

In the same groups of 83 patients and 2559 controls, we have previously detected⁶ a strong association (p<0.0001) between T-1131C and C-1131C genotypes and extreme concentrations of plasma TGs. There is no linkage disequilibrium between rare alleles of both APOAV polymorphisms, thus the effect of both polymorphisms is independent.

Although the exact mechanism by which APOAV influences the plasma concentrations of TGs is unknown, the present results support the notion that this newly described gene is one of the most important genetic determinants of plasma triglycerides detected so far.

Our study included 83 unrelated hypertriglyceridaemic patients and 2559 representatively selected controls from the same population and suggested a strong association between the Ser19→Trp polymorphism in the APOAV gene and extreme concentrations of plasma TGs.

ACKNOWLEDGEMENTS

This work was partly supported by Grant No CEZ:L17/98:00023001 from the Grant Agency of the Czech Republic and by Grant No NB/5986–3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic.

Authors' affiliations

M Vrablík, A Hořínek, R Česka, 3rd Internal Department, 1st Medical Faculty, Charles University, Prague, Czech Republic

V Adámková, R Poledne, J A Hubacek, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

R Poledne, J A Hubacek, Centre for Experimental Cardiovascular Research, Prague, Czech Republic

Correspondence to: Dr J A Hubacek, IKEM - LVA, Videnska 1958/9, 140 21 Prague 4, Czech Republic; jahb@medicon.cz

REFERENCES

- Hokanson JE**, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *J Cardiovasc Risk* 1996;**3**:213–9.
- Pennacchio LA**, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. *Science* 2001;**294**:169–73.
- Talmud PJ**, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. *Hum Mol Genet* 2002;**11**:3039–46.
- Pennacchio LA**, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein AV haplotypes influence human plasma triglyceride levels. *Hum Mol Genet* 2002;**11**:3031–8.
- Ribalta J**, Figuera L, Fernandez-Ballart J, Vilella E, Castro-Cabezas M, Masana L, Joven J. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. *Clin Chem* 2002;**48**:1597–600.
- Hořínek A**, Vrablík M, Česka R, Adámková V, Poledne R, Hubacek JA. T-1131→C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. *Atherosclerosis* 2003;**167**:369–70.
- Miller SA**, Dykes DD, Polesky HF. A simple salting out procedure for DNA extraction from human nucleated cells. *Nucleic Acid Res* 1988;**16**:1215.
- Day IN**, Humphries SE. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. *Anal Biochem* 1994;**222**:389–95.